10/7/2013 9:28:31 AM
Stockholm, Sweden — Medivir AB (OMX: MVIR) announced that data from the phase
IIa COSMOS study (Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1
infected patientS) of the investigational protease inhibitor simeprevir (TMC435)
administered once daily with Gilead’s investigational nucleotide inhibitor
sofosbuvir (GS-7977), with and without ribavirin, in genotype 1 chronic
hepatitis C adult patients with compensated liver disease has been accepted as a
late-breaking oral presentation at the upcoming Annual Meeting of the American
Association for the Study of Liver Diseases (AASLD). AASLD will take place
November 1 to 5 in Washington, D.C.
Help employers find you! Check out all the jobs and post your resume.
comments powered by